Finding could have implications for other autoimmune disorders, such as type I diabetes
Scientists from the Gladstone Institutes have discovered a way to prevent the development of multiple sclerosis (MS) in mice. Using a drug that blocks the production of a certain type of immune cell linked to inflammation and autoimmunity, the researchers successfully protected against the onset of MS in an animal model of the disease. The scientists say the next step is to test this strategy using other autoimmune disorders.
“We are very excited about these findings,” says Eric Verdin, MD, a senior investigator at Gladstone and co-senior author on the study. “In light of the significant effect the treatment had on inflammation, the implications of these results will likely extend beyond multiple sclerosis to other types of autoimmune disorders. We are particularly interested in testing this in type I diabetes given the similar pathways involved, and we are already seeing very promising results in preliminary experiments.”
In the immune system, two kinds of T cells strike a delicate balance–T helper cells (Th17) activate the immune system, protecting against infections and cancers, while regulatory T cells (Tregs) suppress the system, keeping it in check. A disparity between these cell types, where there are too many Th17 and not enough Tregs, can lead to a hyperactive immune system, resulting in inflammation, tissue damage, and autoimmune disease.
In the current study, published in the Journal of Experimental Medicine, the researchers discovered that an important regulatory protein, sirtuin 1 (SIRT1), is involved in the production of Th17 cells. By blocking this protein, the scientists can protect against the onset of autoimmunity. SIRT1 also has a negative impact on Treg maturation and maintenance, so inhibiting its expression simultaneously enhances the production of Tregs and suppresses the creation of Th17.
To test this effect on disease, the researchers used a mouse model of MS and treated the animals with a drug that inhibits SIRT1. Typically, MS-model mice experience severe motor problems, eventually leading to paralysis, but when they were given the drug the mice behaved perfectly normally. Moreover, the treated animals showed no signs of inflammation or cell damage in their spines, classic markers for MS.
The Latest on: Inflammation and autoimmunity
via Google News
The Latest on: Inflammation and autoimmunity
- Gaining insight into organ-specific inflammation through “multiscale imaging”on November 27, 2020 at 3:38 pm
Whenever tissue is damaged in the body – e.g. through infarctions, autoimmune diseases and infections – inflammation occurs. It is the immune system’s instantanious reaction to external stimuli and ...
- Autoimmune Disease Therapeutics Market Excessive Growth Opportunities Estimated to be Experienced 2019-2026on November 26, 2020 at 2:28 am
The global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025. Immune ...
- BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10on November 25, 2020 at 10:50 pm
PRNewswire/ -- Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer ...
- 'Dramatic' Inflammation Reduction After OHCA With Tocilizumabon November 24, 2020 at 10:46 am
A pilot study showed reduced systemic inflammatory response and cardiac injury in out-of-hospital cardiac arrest patients, with the hope of affecting mortality and neurologic outcome in larger trials.
- Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in Chinaon November 24, 2020 at 2:00 am
Nov 24, 2020-- Biopharmaceutical company Alvotech hf. and Alvotech & CCHT Biopharmaceutical Co., Ltd., which is the China joint venture company of Alvotech hf. and Changchun High & New Technology ...
- FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodieson November 23, 2020 at 10:31 pm
FairJourney Biologics S.A (FJB) and IONTAS Limited, leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies ...
- 7 diseases you can keep away by just controlling inflammation in your bodyon November 23, 2020 at 3:43 pm
Inflammation in the airways can also cause airway oedema ... blood pressure), and activation of sensory nerve endings,” explains Dr Singh. 3. You can get autoimmune diseases like arthritis ...
- Sleep apnea and autoimmune diseases: How are they connected?on November 20, 2020 at 6:17 pm
A recent study finds that abnormal levels of inflammatory cytokines in people with obstructive sleep apnea may be linked with autoimmune diseases.
- Global Autoimmune Disorder Drug Delivery Devices Market to 2030on November 19, 2020 at 1:00 pm
The global market for autoimmune disorder drug delivery devices is predicted to grow at a CAGR of 15.25% over the forecast period of 2020-2030. Healthcare experts have found the autoimmune disorders ...
- Anti-Inflammatory Drugs Market to Exhibit 9.3% CAGR by 2027 Owing to Rising Prevalence of Inflammatory Health Conditions: Fortune Business Insights™on November 19, 2020 at 3:52 am
The global “anti-inflammatory market size” is expected to reach USD 191.42 billion by 2027 on account of increasing investments on the development of biologics for treating autoimmune inflammatory ...
via Bing News